Severe sleep apnea, Cheyne-Stokes respiration and desaturation in patients with decompensated heart failure at high altitude

Objectives: To determine the sleep-disordered breathing in patients with decompensated HF (DHF) at an altitude of 2640m.

Methods: Polysomnogram during the first 48 hours of admission in patients hospitalized for DHF. Sleep apnea (SA) was defined as an apnea hypopnea index (AHI) > 5/hour and central sleep apnea (CSA) as central apnea index (CAI) ≥ 50% of the AHI.

Results: Sixteen participants, LVEF 24.2±9.9%. All patients had SA, severe in 12 (75%), CSA in 8 (50%) and 7 (43.8%) presented Cheyne-Stokes respiration (CSR). Out of the eight patients with obstructive SA, five had a central component (CAI ≥ 5/h). The SpO2 decreased during sleep to 80.6±5.5% and in patients with CSR to 77.6±6.9%.

Conclusions: At an altitude of 2640m all patients with DHF presented sleep apnea, most were severe, with CSA and a significant percentage of CSR that was associated with higher oxygen desaturation.

 

Scroll to top

Heart Failure - Sleep Apnea - Central Apnea - Cheyne-Stokes Respiration - Altitude

INTRODUCTION

The estimated prevalence of heart failure (HF) in the European Union is 6.5 million, the prevalence reported by the European Society of Cardiology is 15 million people, and it has increased worldwide consistent with population aging, estimating that more than 23 million people have the disease[1].

Sleep-disordered breathing (SDB) is frequent in patients with HF and the factors associated with it are instability in the ventilatory control, upper airway closure due to secondary edema by redistribution of fluid during supine position and obesity[2]. Sleep apnea (SA) prevalence in patients with a reduced ejection fraction is between 47 to 76%[3], and in those with a preserved ejection fraction is 62%[4]. The presence of obstructive sleep apnea in these patients is an independent risk factor for mortality. Despite this, the SDB in patients with HF are not diagnosed or treated[3] ^, [5].

The frequency of central sleep apneas in patients with heart failure and ventricular dysfunction ranges from 34 to 46%[6]. Variability can be explained by different factors such as age, gender, presence of hypocapnia or atrial fibrillation[7]. Additionally, it is associated with a lower ejection fraction, as well as a worse functional class[8]. In patients with stable severe heart failure, Cheyne-Stokes respiration (CSR) has been described in 30 to 50% of patients. The main mechanism is the fluctuation of PaCO₂ above and below the apnea threshold; and in HF they is associated with low PaCO₂ both in wakefulness and in sleep, prolonged circulation time and probably hypoxemia[9] ^- [11].

Altitude confers an additional risk of central sleep apneas. At 2,000m, this type of respiratory events can appear in individuals without cardiac comorbidity, with a direct correlation between higher altitude and severity of central sleep apnea[12]. At the altitude of Bogota, the lower PaO₂ and PaCO₂ may come closer to the critical apnea threshold values could increase the presentation of CSR[13].

It has been described that the diagnostic approach of sleep-disordered breathing (SDB) in patients hospitalized for decompensated heart failure (DHF) is a tool that allows the initiation of an adequate treatment in a shorter period of time, which may impact several outcomes[14] ^, [15]. Because the characteristics of sleep disorders in DHF at an altitude of 2640m are unknown, our objective was to describe the polysomnogram (PSG) findings in the first 48 hours of hospitalization of these patients.

 

Scroll to top

MATERIALS AND METHODS

Patients

An analytical cross-sectional study was conducted in subjects older than 18 years old, living in Bogotá (altitude: 2,640m) hospitalized for DHF at the Fundación Cardioinfantil, Instituto de Cardiología. Patients with left ventricular ejection fraction < 45%, clinical signs of decompensated heart failure and elevated brain-natriuretic peptide (BNP) values were included. We excluded those with a previous diagnosis of sleep apnea or CPAP use, and those who required hospitalization in intensive care or permanent oxygen use. The research ethics committee approved the study and all subjects signed an informed consent.

 

Scroll to top

Polysomnography

Diagnostic type 2 polysomnography (PSG) were done within the first 48 hours of hospital admission for DHF, with Alice PDx (PhilipsRespironics, Murrysville, PA, USA), using montage as follows: two channels of electroencefalography (EEG) (C3, C4), electroculogram, submental and leg electromiogram, nasal airflow (P-TAF, Pro-Tech, Mukilteo, WA, USA), and thermistor (Respironics^®), Respiratory inductance plethysmography (ZRIP), finger pulse oxymetry (Nonin^®), electrocardiogram (DII), snoring and body position. Manual scoring of the study was done according to American Academy Sleep Medicine rules[16]. A minimum duration of sleep of 180 minutes was accepted.

 

Scroll to top

Definitions

Apnea was defined as a reduction of inspiratory airflow by ≥ 90% over 10 seconds, is obstructive if it meets apnea criteria and is associated with inspiratory effort, central if is associated with absent inspiratory effort and mixed if it meets apnea criteria and is associated with absent inspiratory effort in the initial portion of the event, followed by resumption of inspiratory effort in the second portion of the event; hypopnea was defined as a reduction of of inspiratory airflow by 30% from baseline lasting 10 seconds and accompanied by a 3% desaturation in oxygen. Cheyne-Stokes Breathing was scored when there were > 3 consecutive central apneas separated by a crescendo and decrescendo change in breathing amplitude with a central index > 5/h over > 2 hours of monitoring. Oxygen Desaturation Index (ODI) was the number of drops of SpO₂ greater than 3% per hour of sleep[16].

Statistical analysis

The distribution of the quantitative variables was evaluated using the Kolmogorov-Smirnoff test and they were presented as means and standard deviations or medians and interquartile ranges. Proportions were used for the qualitative variables. The clinical and PSG characteristics were compared among patients with central sleep apnea and obstructive apnea and among the groups with and without Cheyne-Stokes respiration. For continuous variables, Student’s t-test for independent samples or the Mann-Whitney U test was used and for the qualitative variables, the chi-square test or the Fisher’s exact test when the expected frequencies were less than 5. Hypotheses were formulated with two-tailed tests with a significance level of less than 0.05. The SPSS statistical software, version 10.0, was used.

 

Scroll to top

 

Scroll to top

 

Scroll to top

RESULTS

Participants

We included 16 patients with decompensated heart failure, 75% men, aged 63.5±13.9. The left ventricular ejection fraction (LVEF) was 24.2±9.9%, 93.8% of the subjects were in NYHA class III-IV, 56.3% had ischemic heart disease and 43.8% had atrial fibrillation. The other demographic, clinical and echocardiographic variables are shown in [Table 1].

Table 1 Demographic and clinical characteristics.

	Total (N=16)	Obstructive Apnea (N=8)	Central Apnea (N=8)	p
Age, years	63.5±13.9	64.4±11.6	62.6±16.6	0.811
Men	12 (75.0)	5 (62.5)	7 (87.5)	0.569
BMI, kg/cm2	26.5±4.6	28.8±4.4	24.3±3.7	0.041
Neck circumference, cm	37.9±4.2	38.5±2.8	37.4±5.3	0.623
Snoring	10 (62.5)	7 (87.5)	3 (37.5)	0.119
Observed pauses	7 (43.8)	5 (62.5)	2 (25.0)	0.315
Epworth Scale	8.5±4.9	9.1±6.6	7.9±2.7	0.632
Cause
• Ischemic	9 (56.3)	6 (75.0)	3 (37.5)	0.315
• Dilated	4 (25.0)	1 (12.5)	3 (18.7)	0.569
• Other causes	3 (18.7)	2 (25.0)	1 (12.5)	0.999
Stage
• C	13 (81.3)	6 (75.0)	7 (87.5)
• D	3 (18.8)	2 (25.0)	1 (12.5)	0.999
Functional class
• II	1 (6.3)	1 (12.5)	0 (0.0)
• III	12 (75.0)	6 (75.0)	6 (75.0)
• IV	3 (18.8)	1 (12.5)	2 (25.0)	0.513
LVEF, %	24.2±9.9	25.0±11.6	23.4±8.4	0.754
Pulmonary Hypertension	11 (68.8)	7 (87.5)	4 (50.0)	0.282
Diabetes	6 (37.5)	2 (25.0)	4 (50.0)	0.608
Systemic Hypertension	10 (62.5)	4 (50.0)	6 (75.0)	0.608
Atrial fibrillation	7 (43.8)	4 (50.0)	3 (37.5)	0.999
Chronic renal disease	4 (25.0)	3 (37.5)	1 (12.5)	0.569
Receiving
• Diuretics	12 (75.0)	6 (75.0)	6 (75.0)	0.999
• Beta-bloquers	11 (68.8)	6 (75.0)	5 (62.5)	0.999
• ACE inhibitors	4 (25.0)	1 (12.5)	3 (37.5)	0.569
• Digital	2 (12.5)	2 (25.0)	0 (0.0)	0.467

Values as mean ± DE o N (%) BMI: Body mass index; LVEF: Left ventricle ejection fraction; ACE: angiotensin converting enzyme. p=differences between obstructive and central apnea

 

Scroll to top

Variables in the polysomnogram

In all subjects, sleep efficiency was low with a high arousal index. The 16 subjects had sleep apnea (AHI 45.5±21.6), 75% severe, 50% central sleep apnea (CAI > 50% of total AHI) and 7 (43.8%) Cheyne-Stokes respiration. Of the 8 patients with obstructive sleep apnea, 5 had a central component (CAI > 5). In patients with central SAHS, respiratory events occurred more frequently in non-REM sleep (p=0.005) and in supine (p=0.034). In all subjects with central and obstructive apnea, the desaturation index and the T₉₀ were elevated, with a significant drop in oxygen saturation during respiratory events ([Table 2]).

Table 2 Polysomnogram characteristics.

	Total (N=16)	Obstructive Apnea (N=8)	Central Apnea (N=8)	p
Sleep efficiency, %	70.8±11.1	70.3±11.3	71.4±11.7	0.846
Arousal index/hour	32.7±16.1	31.5±16.1	34.0±17.2	0.763
AHI, number/hour	45.5±21.6	31.7±17.6	59.3±16.1	0.006
AHI REM, number/hour	31.8±30.8	22.2±34.7	41.5±24.9	0.223
AHI nREM, number/hora	47.1±24.9	31.0±19.6	63.2±18.8	0.005
AHI supine	46.3±26.8	32.5±27.3	60.1±19.0	0.034
AHI lateral	38.1±21.2	34.4±18.0	41.7±24.8	0.510
CAI, number/hour	25.9±22.7	7.4±8.9	44.4±15.7	<0.001
%CA	45.5±32.2	17.5±16.1	73.6±12.8	<0.001
CAI REM, number/hour (N=9)	7.4±10.0	0.3±0.5	11.0±10.7	0.057
CAI nREM, number/hour (N=9)	40.3±27.6	10.0±2.0	55.5±19.8	0.006
Cheyne-Stokes Respiration	7 (43.8)	1 (12.5%)	6 (75.0%)	0.041
OAI, number/hour	4.6±4.1	5.6±4.4	3.6±3.8	0.331
MAI, number/hour	3.6±3.4	3.3±3.4	4.0±3.6	0.727
HI, number/hour	11.4±7.1	15.4±7.4	7.4±4.0	0.018
T90, %	74.2±28.3	71.6±36.0	76.8±20.2	0.157
ODI	53.5±26.5	44.3±31.9	64.1±14.4	0.157
SpO2 wakefulness, %	87.8±4.1	87.3±5.5	88.4±2.3	0.601
SpO2 events, %	80.6±5.5	81.0±7.6	80.3±2.4	0.794

Values as mean ± DE o N (%) AHI: Apnea hypopnea index; CAI: Central apnea index;OAI: Obstructive apnea index; HI: Hypopneas index; SpO2: Oxygen saturation; ODI: oxygen desaturation index. p=differences between obstructive and central apnea.

Subjects with obstructive apnea had a higher body mass index than patients in whom central sleep apnea predominated, without differences between these two groups in age, sleepiness scale, LVEF, type of heart disease, functional class, comorbidities or medications ([Table 1]).

 

Scroll to top

Cheyne-Stokes respiration

In patients with Cheyne-Stokes respiration AHI, CAI, desaturation index, T₉₀ and desaturation during respiratory events were higher than in those without Cheyne-Stokes ([Table 3]) ([Figure 1]). Among these groups there were no differences in age, BMI, Epworth, antecedent of atrial fibrillation or LVEF.

Table 3 Patients with and without Cheyne-Stokes.

	Cheyne-Stokes (-) (N=9)	Cheyne-Stokes (+) (N=7)	p
Age, years	66.9±12.4	59.1±15.4	0.283
BMI, kg/m2	27.0±5.8	26.0±2.7	0.699
Neck circumference, cm	37.4±3.3	38.6±5.5	0.625
Epworth Scale	9.7±5.8	7.0±3.3	0.298
Atrial fibrillation	4 (44.4)	3 (42.9)	0.999
LVEF, %	25.0±10.9	23.1±9.1	0.722
Sleep efficiency, %	66.4±11.8	76.5±7.5	0.071
AHI, number/h	34.4±21.0	59.7±12.8	0.014
CAI, number/h	12.4±18.0	43.2±15.4	0.003
AHI REM, number/h	12.4±14.6	56.7±28.4	0.001
AHI NREM, number/h	36.2±26.9	61.1±13.5	0.043
AHI supine, number/h	44.3±27.0	48.8±28.5	0.754
AHI lateral, number/H	26.9±17.9	52.4±16.6	0.011
T90, %	71.3±33.1	77.9±22.9	0.672
ODI	39.3±20.5	74.9±19.4	0.006
SpO2 wakefulness, %	88.7±2.3	86.7±5.7	0.363
SpO2 events, %	83.0±2.4	77.6±6.9	0.044

Values as mean ± DE o N (%) BMI: Body mass index; LVEF: Left ventricle ejection fraction; AHI: Apnea hyponea Index; AHI: Apnea hypopnea index; CAI: Central apnea index; ODI: oxygen desaturation index; SpO2: Oxygen saturation p=differences between patients with and without CSR.

Figure 1 Oxygen saturation during wakefulness and sleep in patients with and without Cheyne-Stokes respiration Legenda: Subjects with Cheyne-Stokes had more desaturation during sleep respiratory events (p=0.044). SpO2: Oxygen saturation.

 

Scroll to top

 

Scroll to top

DISCUSSION

The main finding of this study is that all patients included with DHF presented SA, most were severe, with the presence of central sleep apneas and with a significant percentage of Cheyne-Stokes respiration that was associated with higher desaturation.

Unlike other studies, all patients studied at the altitude had SA and in 75% of the cases it was severe. Sharma et al.[17], in a recent publication, described sleep-disordered breathing in 91 of 105 hospitalized patients with decompensated heart failure, of whom only 40% had severe SAHS. In the work of Kauta et al.[14], 78% of patients had AHI > 5/h.

The severity of SA in the patients included in this study may be explained by a lower ejection fraction (24.2±9.9) compared to the Sharma group (36.4±20.5) and Kauta (36.3±21.2), as well as a worse functional class and stage of heart failure (C and D), conditions that influence the pathophysiology of SA in these patients[3] ^, [18]. Unlike our study, in both aforementioned studies, the proportion of patients with predominantly central SA (CAI > 50% of total AHI) was significantly lower[17]. Similarly, the central sleep apnea index for the total group of patients with DHF (25.9±22.7) is markedly greater than that described in a previous study conducted by our group at the same altitude in subjects without heart failure, suggesting that the occurrence of central sleep apnea is not explained by altitude alone[19].

In healthy individuals, the exposure to hypobaric hypoxia at high altitude causes an increase in the ventilatory drive triggering a pattern of alternating central sleep apneas and hypopneas with hyperventilation, oscillations of oxygen saturation and usually accompanied by arousals. In heart failure patients, abnormalities in CO₂ chemoreceptor response have been demonstrated and may be the main determinant of the presence of Cheyne-Stokes, triggering respiratory events when PaCO₂ falls below the apneic threshold[20]. Hypoxemia amplifies this response and it may explain the greater presence of Cheyne-Stokes respiration in these patients[12] ^, [21].

It has also been shown that AHI is greater in patients with sleep apnea at 2,400m compared to those at lower altitudes (1,370m and at sea level), decreasing at the expense of fewer central events[22]. Oxygen saturation is significantly decreased at 1,860m and markedly at 2,590m[23].

Patients described in this study had desaturation during wakefulness, with a significant decrease during respiratory events, with no differences between groups, which correlates with the severity of heart disease worsened by physiological changes related to altitude[24]. We do not know the impact that the elevated desaturation index and the severity of the desaturation may have in the evolution, control and prognosis of the disease[6] ^, [25].

We found a significant number of patients with CSR in the upper range of what is described in the literature[11]. This could be related to the lower PaO₂ and PaCO₂ in the altitude of Bogota which are closer to the critical apnea threshold values[13]. Patients with CSR presented higher AHI (59.7±12.8) than those without CRS (34.4±21.0) and severity was not modified with the lateral decubitus position as described by Szollosi et al.[26]. Although T₉₀ was similar among those who presented CSR and those who did not, we found a higher desaturation index and more severe desaturation during the respiratory events in CRS, in contrast to what was found in some reports where both PaO₂ in wakefulness and SpO₂ during sleep were normal and practically identical in patients with HF with and without CSR[11].

There is some evidence that the presence of CSR is a marker of poor prognosis, with some contradictory data. However, it appears to have some deleterious impact, mediated by peaks in systemic blood pressure and heart rate, and by arousals related to increased sympathetic activity[27].

The beta-blocker use rate was 68.8% in the total group, with no difference between the subgroups (obstructive and central) which has previously been described as a factor that does not influence the decrease in the proportion of central events[28]. Although atrial fibrillation has been described as a predictor of Cheyne-Stokes[29], in this group of patients there was no difference in the antecedent of atrial fibrillation between those with and without CSR (42.9% vs. 44.4%, p=0.99).

Some limitations of the study are the small sample size and the lack of follow-up of patient outcomes. However, there was a careful selection of patients using clinical and laboratory criteria to classify them as DHF; only subjects living at high altitude were included and they were evaluated in the first 48 hours of hospitalization with a type 2 polysomnographic study without supplemental oxygen. To our knowledge, this is the first study performed at the altitude, describing respiratory disorders during sleep in patients with decompensated heart failure, which increases the knowledge of these pathologies at altitude. Further studies are required with a larger sample of subjects to assess the impact of SDB and treatment received.

 

Scroll to top

CONCLUSION

At an altitude of 2,640m, all patients studied with DHF presented sleep apnea, most were severe, with the presence of central sleep apneas and with a significant percentage of Cheyne-Stokes respiration that was associated with higher desaturation.

 

Scroll to top

 

Scroll to top

Conflict of Interests

The authors have no conflict of interests to declare.

• REFERENCES

• 1 Bloom MW, Greenberg B, Jaarsma T, Januzzi JL, Lam CSP, Maggioni AP, et al. Heart failure with reduced ejection fraction. Nature Rev Dis Primers. 2017;3:17058.
• 2 Kasai T, Floras JS, Bradley TD. Sleep apnea and cardiovascular disease: a bidirectional relationship. Circulation. 2012;126(12):1495-510.
• 3 Sharma B, Owens R, Malhotra A. Sleep in congestive heart failure. Med Clin North Am. 2010;94(3):447-64.
• 4 Herrscher TE, Akre H, Øverland B, Sandvik L, Westheim AS. High prevalence of sleep apnea in heart failure outpatients: even in patients with preserved systolic function. J Card Fail. 2011;17(5):420-5.
• 5 Dharia SM, Brown LK. Epidemiology of Sleep-Disordered Breathing and Heart Failure: What Drives What. Curr Heart Fail Rep. 2017;14(5):351-4.
• 6 Javaheri S, Barbe F, Campos-Rodriguez F, Dempsey JA, Khayat R, Javaheri S, et al. Sleep Apnea: Types, Mechanisms, and Clinical Cardiovascular Consequences. J Am Coll Cardiol. 2017;69(7):841-58.
• 7 Grimm W, Sass J, Sibai E, Cassel W, Hildebrandt O, Apelt S, et al. Severe central sleep apnea is associated with atrial fibrillation in patients with left ventricular systolic dysfunction. Pacing Clin Electrophysiol. 2015;38(6):706-12.
• 8 Naughton MT. Epidemiology of central sleep apnoea in heart failure. Int J Cardiol. 2016;206 Suppl:S4-7.
• 9 Naughton M, Benard D, Tam A, Rutherford R, Bradley TD. Role of hyperventilation in the pathogenesis of central sleep apneas in patients with congestive heart failure. Am Rev Respir Dis. 1993;148(2):330-8.
• 10 Crowell JW, Guyton AC, Moore JW. Basic oscillating mechanism of Cheyne-Stokes breathing. Am J Physiol. 1956;187(2):395-8.
• 11 Sin DD, Fitzgerald F, Parker JD, Newton G, Floras JS, Bradley TD. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J Respir Crit Care Med. 1999;160(4):1101-6.
• 12 Burgess KR, Johnson PL, Edwards N. Central and obstructive sleep apnoea during ascent to high altitude. Respirology. 2004;9(2):222-9.
• 13 Maldonado D, Gonzalez-Garcia M, Barrero M, Casas A, Torres-Duque C. Reference Values For Arterial Blood Gases At An Altitude Of 2640 Meters. C76. In: American Thoracic Society 2013 International Conference; 2013 May 17-22; Philadelphia PA USA. Am J Respir Crit Care Med. 2013;187:A4852.
• 14 Kauta SR, Keenan BT, Goldberg L, Schwab RJ. Diagnosis and treatment of sleep disordered breathing in hospitalized cardiac patients: a reduction in 30-day hospital readmission rates. J Clin Sleep Med. 2014;10(10):1051-9.
• 15 Sharma S. Hospital sleep medicine: the elephant in the room? J Clin Sleep Med. 2014;10(10):1067-8.
• 16 Berry RB, Brooks R, Gamaldo CE, Harding SM, Lloyd RM, Marcus CL, et al. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, Version 2.2. Darien, Il: American Academy of Sleep Medicine; 2015.
• 17 Sharma S, Mather PJ, Chowdhury A, Gupta S, Mukhtar U, Willes L, et al. Sleep Overnight Monitoring for Apnea in Patients Hospitalized with Heart Failure (SOMA-HF Study). J Clin Sleep Med. 2017;13(10):1185-90.
• 18 Lévy P, Pépin JL, Tamisier R, Neuder Y, Baguet JP, Javaheri S. Prevalence and Impact of Central Sleep Apnea in Heart Failure. Sleep Med Clin. 2007;2(4):615-21.
• 19 Bazurto Zapata MA, Martinez-Guzman W, Vargas-Ramirez L, Herrera K, Gonzalez-Garcia M. Prevalence of central sleep apnea during continous positive airway pressure (CPAP) titration in subjects with obstructive sleep apnea syndrome at an altitude of 2640 m. Sleep Med. 2015;16(3):343-6.
• 20 Wilcox I, Grunstein RR, Collins FL, Berthon-Jones M, Kelly DT, Sullivan CE. The role of central chemosensitivity in central apnea of heart failure. Sleep. 1993;16(8 Suppl):S37-8.
• 21 Bloch KE, Latshang TD, Ulrich S. Patients with Obstructive Sleep Apnea at Altitude. High Alt Med Biol. 2015;16(2):110-6.
• 22 Patz D, Spoon M, Corbin R, Patz M, Dover L, Swihart B, et al. The effect of altitude descent on obstructive sleep apnea. Chest. 2006;130(6):1744-50.
• 23 Nussbaumer-Ochsner Y, Schuepfer N, Ulrich S, Bloch KE. Exacerbation of sleep apnoea by frequent central events in patients with the obstructive sleep apnoea syndrome at altitude: a randomised trial. Thorax. 2010;65(5):429-35.
• 24 San T, Polat S, Cingi C, Eskiizmir G, Oghan F, Cakir B. Effects of high altitude on sleep and respiratory system and theirs adaptations. ScientificWorldJournal. 2013;2013:241569.
• 25 Costanzo MR, Khayat R, Ponikowski P, Augostini R, Stellbrink C, Mianulli M, et al. Mechanisms and clinical consequences of untreated central sleep apnea in heart failure. J Am Coll Cardiol. 2015;65(1):72-84.
• 26 Szollosi I, Roebuck T, Thompson B, Naughton MT. Lateral sleeping position reduces severity of central sleep apnea / Cheyne-Stokes respiration. Sleep. 2006;29(8):1045-51.
• 27 Lorenzi-Filho G, Genta PR, Figueiredo AC, Inoue D. Cheyne-Stokes respiration in patients with congestive heart failure: causes and consequences. Clinics (São Paulo). 2005;60(4):333-44.
• 28 Zhao ZH, Sullivan C, Liu ZH, Luo Q, Xiong CM, Ni XH, et al. Prevalence and clinical characteristics of sleep apnea in Chinese patients with heart failure. Int J Cardiol. 2007;118(1):122-3.
• 29 Blackshear JL, Kaplan J, Thompson RC, Safford RE, Atkinson EJ. Nocturnal dyspnea and atrial fibrillation predict Cheyne-Stokes respirations in patients with congestive heart failure. Arch Intern Med. 1995;155(12):1297-302.

Publikationsverlauf

Eingereicht: 05. Februar 2018

Angenommen: 29. Mai 2018

Artikel online veröffentlicht:
13. Oktober 2023